Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session - NETs and endocrine tumours

1096O - Lanreotide autogel/depot (LAN) in patients with advanced bronchopulmonary (BP) neuroendocrine tumors (NETs): Results from the phase III SPINET study

Date

21 Sep 2021

Session

Proffered Paper session - NETs and endocrine tumours

Presenters

Dieter Horsch

Citation

Annals of Oncology (2021) 32 (suppl_5): S906-S920. 10.1016/annonc/annonc678

Authors

D. Horsch1, E. Baudin2, S. Singh3, M.E. Caplin4, D. Ferone5, E.M. Wolin6, J. Capdevila7, W.A. Buikhuisen8, M. Raderer9, E. Dansin10, C. Grohe11, A. Houchard12, X. TRUONG THANH13, D. Reidy-Lagunes14

Author affiliations

  • 1 Internal Medicine/gastroenterology And Endocrinology, Zentralklinik Bad Berka GmbH, 99437 - Bad Berka/DE
  • 2 Endocrine Oncology Unit (imaging), Gustave Roussy Institut de Cancerologie, 94805 - Villejuif/FR
  • 3 Medical Oncology And Hematology, Sunnybrook Odette Cancer Center, Sunnybrook HSC, M4N 3M5 - Toronto/CA
  • 4 Neuroendocrine Tumour Unit, Royal Free Hospital School of Medicine, NW3 2QG - London/GB
  • 5 Neuroendocrine Tumour Unit, Department Of Internal Medicine & Medical Specialties, University of Genova, 16132 - Genova/IT
  • 6 -, Icahn School of Medicine at Mount Sinai, 90048 - New York/US
  • 7 Medical Oncology Department, Vall d'Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), 08035 - Barcelona/ES
  • 8 Department Of Thorax Oncology, Netherlands Cancer Institute, 1066CX - Amsterdam/NL
  • 9 Department Of Oncology, Medical University of Vienna, A-1090 - Vienna/AT
  • 10 Thoracic Oncology, Centre Oscar Lambret, 59020 - Lille/FR
  • 11 Department Of Respiratory Diseases, ELK, 13125 - Berlin/DE
  • 12 Data And Insights Generation And Strategy, Ipsen, 92100 - Boulogne/FR
  • 13 Global Medical Affairs, Ipsen, 92100 - Boulogne Billancourt/FR
  • 14 Medicine, Memorial Sloan Kettering Cancer Center, 10128 - New York City/US
More

Resources

Login to access the resources on OncologyPRO.

Abstract 1096O

Background

Well-differentiated BP-NETs (typical and atypical carcinoid; TC and AC) account for ∼25% of all NETs. However, there is a lack of prospective data with somatostatin analogs (SSAs) in BP-NETs. SPINET evaluated LAN in advanced somatostatin receptor (SSTR)-positive TC and AC BP-NETs.

Methods

SPINET (EudraCT 2015-004992-62; NCT02683941) was a phase 3, randomized (2 LAN: 1 PBO, stratified by TC vs AC), double-blind (DB) study of LAN (120 mg/28 days), with optional open-label LAN treatment phase (OL-LAN). Enrollment was stopped due to slow accrual and ongoing patients in the DB phase could transition to open-label LAN. The primary endpoint was adapted: centrally assessed (RECIST 1.1) PFS during the DB/OL-LAN phases in patients randomized to LAN. Secondary endpoints included PFS and objective response rate (ORR) [central] and time to treatment failure (TTF) [local/central] in each treatment arm during DB phase, and safety.

Results

Overall, 77 patients were randomized and treated (intention-to-treat set: LAN, n=51; PBO, n=26; [OL-LAN, n=40]). Mean (SD) age was 66.2 (12.5) years and 42 (54.5%) were male; 45 (58.4%) and 32 (41.6%) patients had TC and AC respectively, all (Octreoscan) patients had a Krenning score ≥2, 6 (7.8%) had received prior cytotoxic chemotherapy, 71 (92.2%) had hepatic tumor load ≤25%, and 28 (57.1%) and 19 (38.8%) patients had liver and bone metastases, respectively. Median (95% CI) PFS in the LAN randomized group was 16.6 (12.8–21.9) months (TC 21.9 [12.8–not calculable (NC)] months; AC 14.1 [5.6–16.6] months). Key secondary endpoints are shown in the table. In the DB phase, PFS for LAN and PBO, respectively, was 21.9 (13.8–NC) vs 13.9 (13.4–NC) months in TC and 13.8 (5.6–16.6) vs 11.0 (2.8–16.9) months in AC. Table: 1096O

DB
LAN (n=51) PBO (n=26) HR [95% CI]a
PFS (TC & AC), median (95% CI), mths 16.6 (11.3–21.9) 13.6 (8.3–NC) 0.90 [0.46–1.88]
ORR, % (95% CI) 14.0 (5.8–26.7) 0 (0.0–13.7)
TTF, median (95% CI), mths 13.3 (5.6–14.1) 9.8 (5.4–13.6) 0.86 [0.50–1.50]
DB OL-LAN
TEAEs, n (%)b LAN (n=51) PBO (n=26) All pts (n=40)
Any 49 (96.1) 25 (96.2) 26 (65.0)
Related 38 (74.5) 14 (53.8) 13 (32.5)
Grade12345 44 (86.3)37 (72.5)13 (25.5)1 (2.0)1 (2.0) 23 (88.5)19 (73.1)8 (30.8)00 25 (62.5)14 (35.0)3 (7.5)00
Leading to study treatment withdrawal 2 (3.9) 3 (11.5) 0
Serious AEs 10 (19.6) 7 (26.9) 1 (2.5)
Related 2 (3.9) 1 (3.8) 0

aLAN vs PBO; bExcludes death/progression (part of PFS assessment) TEAE, treatment-emergent adverse event.

Conclusions

SPINET, the largest prospective study to date with a SSA in SSTR-positive BP-NETs, suggests that LAN 120 mg could be an appropriate treatment option, especially for TC.

Clinical trial identification

EudraCT 2015-004992-62; NCT02683941.

Editorial acknowledgement

Dr Nicky French of Oxford PharmaGenesis, Oxford, UK, provided medical writing and editorial support, which was sponsored by Ipsen.

Legal entity responsible for the study

Ipsen.

Funding

Ipsen.

Disclosure

E. Baudin: Financial Interests, Personal and Institutional, Expert Testimony, Advisory Board, Research grant, Principal Investigator: Novartis; Financial Interests, Personal and Institutional, Advisory Board, Research grant: HRA; Financial Interests, Personal and Institutional, Project Lead, Principal Investigator: Ipsen; Financial Interests, Personal and Institutional, Advisory Board, Research grant: AAA; Financial Interests, Personal and Institutional, Research Grant: Pfizer; Financial Interests, Personal and Institutional, Advisory Board: Hutchinson Pharma. D. Horsch: Financial Interests, Personal, Advisory Board: Advanz Pharma; Financial Interests, Personal, Advisory Board: Novartis Pharma GmbH; Financial Interests, Personal, Advisory Board: Ipsen Pharma GmbH; Financial Interests, Personal, Invited Speaker: Ipsen Pharma GmbH. S. Singh: Financial Interests, Institutional, Research Grant: AAA; Financial Interests, Institutional, Research Grant: Ipsen; Financial Interests, Personal, Advisory Board, Invited speaker: Ipsen. M.E. Caplin: Financial Interests, Personal, Speaker’s Bureau, Advisory Board, Research grant: Ipsen; Financial Interests, Personal, Speaker’s Bureau, Advisory Board: Novartis; Financial Interests, Personal, Speaker’s Bureau, Advisory Board, Research grant: Advanced Accelerator Applications; Financial Interests, Personal, Speaker’s Bureau, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Sirtex. D. Ferone: Other, Institutional, Invited Speaker, Advisory Board, Research grant: Ipsen; Other, Institutional, Invited Speaker, Advisory Board, Research grant: Novartis-AAA; Other, Institutional, Invited Speaker, Research grant: Pfizer; Other, Institutional, Advisory Board: Sandoz; Other, Institutional, Advisory Board: BMS; Other, Institutional, Advisory Board, Research grant: Camurus. E.M. Wolin: Non-Financial Interests, Personal, Advisory Board: Chiasma; Non-Financial Interests, Personal, Advisory Board: Progenics; Non-Financial Interests, Personal, Advisory Board: RadioMedix. J. Capdevila: Financial Interests, Personal, Speaker’s Bureau, Advisory Board, Invited speaker: Amgen; Financial Interests, Personal, Speaker’s Bureau, Advisory Board, Invited speaker: Bayer; Financial Interests, Personal, Speaker’s Bureau, Advisory Board, Invited speaker, Research grant: AAA; Financial Interests, Personal, Speaker’s Bureau, Advisory Board, Invited speaker, Research grant: AstraZeneca; Financial Interests, Personal, Speaker’s Bureau, Advisory Board, Invited speaker, Research grant: Eisai; Financial Interests, Personal, Speaker’s Bureau, Advisory Board, Invited speaker: Exelixis; Financial Interests, Personal, Speaker’s Bureau, Advisory Board, Invited speaker, Research grant: Ipsen; Financial Interests, Personal, Speaker’s Bureau, Advisory Board, Invited speaker: ITM; Financial Interests, Personal, Speaker’s Bureau, Advisory Board, Invited speaker: Hudchinson Pharma; Financial Interests, Personal, Speaker’s Bureau, Advisory Board, Invited speaker: Lilly; Financial Interests, Personal, Speaker’s Bureau, Advisory Board, Invited speaker, Research grant: Merck; Financial Interests, Personal, Speaker’s Bureau, Advisory Board, Invited speaker, Research grant: Novartis; Financial Interests, Personal, Speaker’s Bureau, Advisory Board, Invited speaker, Research grant: Pfizer; Financial Interests, Personal, Speaker’s Bureau, Advisory Board, Invited speaker: Sanofi. M. Raderer: Financial Interests, Personal, Other, Honoraria: Gilead; Financial Interests, Personal, Other, Honoraria: Ipsen; Financial Interests, Personal, Other, Honoraria: Novartis; Financial Interests, Personal, Other, Honoraria: Eli Lilly; Financial Interests, Personal, Other, Honoraria: Eisai; Financial Interests, Personal, Other, Honoraria: Roche. C. Grohe: Financial Interests, Institutional, Research Grant: Ipsen. A. Houchard: Financial Interests, Institutional, Stocks/Shares: Ipsen. X. Truong Thanh: Financial Interests, Institutional, Full or part-time Employment, Project Lead, Stocks/Shares: Ipsen. D. Reidy-Lagunes: Financial Interests, Institutional, Principal Investigator, SPINET: Ipsen; Financial Interests, Personal and Institutional, Advisory Board, Research grant: Novartis; Financial Interests, Personal, Advisory Board: AAA; Financial Interests, Personal, Advisory Board: Chiasma. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.